header logo image


Page 588«..1020..587588589590..600610..»

Are Robust Financials Driving The Recent Rally In Avecho Biotechnology Limited’s (ASX:AVE) Stock? – Yahoo Finance

April 19th, 2020 1:46 am

Avecho Biotechnology's's (ASX:AVE) stock is up by a considerable 200% over the past month. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. Particularly, we will be paying attention to Avecho Biotechnology's ROE today.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

View our latest analysis for Avecho Biotechnology

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) Shareholders' Equity

So, based on the above formula, the ROE for Avecho Biotechnology is:

18% = AU$850k AU$4.8m (Based on the trailing twelve months to December 2019).

The 'return' is the income the business earned over the last year. So, this means that for every A$1 of its shareholder's investments, the company generates a profit of A$0.18.

So far, we've learnt that ROE is a measure of a company's profitability. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

To begin with, Avecho Biotechnology seems to have a respectable ROE. Further, the company's ROE compares quite favorably to the industry average of 11%. This certainly adds some context to Avecho Biotechnology's exceptional 32% net income growth seen over the past five years. However, there could also be other causes behind this growth. Such as - high earnings retention or an efficient management in place.

Next, on comparing Avecho Biotechnology's net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 32% in the same period.

ASX:AVE Past Earnings Growth April 17th 2020

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Avecho Biotechnology is trading on a high P/E or a low P/E, relative to its industry.

Avecho Biotechnology doesn't pay any dividend to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above.

In total, we are pretty happy with Avecho Biotechnology's performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings.

Story continues

If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Remember, the price of a stock is also dependent on the perceived risk. Therefore investors must keep themselves informed about the risks involved before investing in any company.

You can see the 3 risks we have identified for Avecho Biotechnology by visiting our risks dashboard for free on our platform here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Excerpt from:
Are Robust Financials Driving The Recent Rally In Avecho Biotechnology Limited's (ASX:AVE) Stock? - Yahoo Finance

Read More...

Cuban Biotechnology develops 15 projects to face the pandemic – Tehran Times

April 19th, 2020 1:46 am

Cuban scientists are working on 15 biotechnological projects to deal with COVID-19 that encompass diagnosis and treatment, officials from the BioCubaFarma entity announced.

Orlando Prez Rodrguez, director of Science and Innovation at BioCubaFarma, said that all clinical research and interventions have been duly authorized by Cuban regulatory entities and will be timely evaluated and reported to publicize Cuba's experience in this field.

He explained that 6 of the 15 projects are focused on treatment, the same number is prophylactic, two are diagnosticians and a medical team.

He added that the products focus on increasing people's innate immunity, reducing the viral load at the beginning of the disease and reducing the hyperinflammatory reaction in patients who develop it, especially in vulnerable groups (older adults or those with pathologies of antecedent).

As a sample of the responsiveness of Cuban Biotechnology, 9 of these projects are already in the phase of intervention trials or clinical studies and six are still in the research and development phase in laboratories, in addition to others in the design or early research.

He pointed out that in the treatment, in the initial stage Interferon Alpha 2B is used, for the management of the inflammatory reaction produced by COVID-19, the monoclonal antibody of the Immunoassay Center and a peptide from the Center for Genetic and Biotechnological Engineering are studied (CIGB).

Most products focus on the use of prophylactics, including nasal administration of interferon Alfa (to stimulate immunity), biomodulin-T (for those over 60 years of age), transfer factor (stimulates immunity in vulnerable groups), CIGB 2020 (immuno enhancer) and a vaccine candidate from the Finlay Institute (contains components of the Cuban meningitis vaccine).

Read this article:
Cuban Biotechnology develops 15 projects to face the pandemic - Tehran Times

Read More...

Role of Cuban science and biotechnology against coronavirus addressed – OnCubaNews

April 19th, 2020 1:46 am

The president of BioCubaFarma, Eduardo Martnez, highlighted in the Mesa Redonda television program that in the fight against the coronavirus, his institution has a plan that covers different aspects, one of which is to guarantee the medicines designed for the protocols. He ensured their availability for patients who could be diagnosed, even in the worst case scenario.

He said that BioCubaFarma has also joined the production of soaps, disinfectants, hydroalcoholic solutions and protection means. He added that the antiviral action of interferon has been shown to be effective in treating the disease, along with other products developed by the biopharmaceutical industry. He said that many countries had asked Cuba for support in the supply of medicines. To date, 62 nations have requested interferon.

He insisted that asymptomatic patients constitute the fundamental cause of the spread of the epidemic; hence the importance of mass screening to identify suspects and isolate them. It is an international and local challenge, he said. This April 12, more than 2,000 tests were made in Cuba to diagnose the disease.

For his part, the director of the Finlay Vaccine Institute, Dr. Vicente Vrez, reported that even though the search for a vaccine will take time, there are other options to improve patients immune systems.

Cuba, he said, today has two vaccines used to fight both cancer and allergies, and they will start being applied to risk groups. Their purpose is aimed at strengthening peoples immune system. He explained that several researchers are working on a project aimed at finding out the incidence of these vaccines in patients to prevent them from developing a serious condition.

However, he said that the most important thing was social isolation, the use of the facemask and eyeglasses. All this makes it possible to put up a barrier against the virus and decrease the viral load in case of illness.

The director of the Center for Genetic Engineering and Biotechnology, Dr. Mara del Carmen Domnguez Orta, said that the institution has a research base of 20 years. A specific product, Molecule 258, is intended to regulate peoples immune systems and control inflammation of the organs without generating immunosuppression.

It has been applied, she said, in three critically ill patients at the IPK and the Naval Hospital with positive results, but, she pointed out, it is only used when there are no other options and with the prior consent of family members.

She stressed that this medicine is not a cure, but a therapeutic alternative, hence the importance of complying with prevention measures.

Lastly, Dr. Gerardo Guilln Nieto, director of Biomedical Research at the Center for Genetic Engineering and Biotechnology, said that the vaccine to strengthen innate immunity to COVID-19 is in the final phase of study.

The vaccine, which is applied sublingually, enhances immunity to the entry of the virus, he said, explaining that the samples analyzed after the application of the drug confirm that it stimulates the molecules that mark the activation of the innate immune system.

That vaccine will be favorable to the most vulnerable groups and will help them stimulate the immune response against the virus.

Here is the original post:
Role of Cuban science and biotechnology against coronavirus addressed - OnCubaNews

Read More...

Unified website for biotechnology regulation recently launched – Daily Herald

April 19th, 2020 1:45 am

WASHINGTON, D.C. In recognition of National Biotechnology Month, the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) recently launched a unified website for biotechnology regulation.

The website streamlines information about the three regulatory agencies charged with overseeing agriculture biotechnology products and is part President Donald J. Trumps Executive Order on Modernizing the Regulatory Framework for Agricultural Biotechnology Products.

Agricultural biotechnology has been and will continue to be an essential tool in helping Americas farmers and ranchers feed, fuel and clothe the world, said U.S. Secretary of Agriculture Sonny Perdue.

From producers to consumers, all Americans deserve a government that delivers science-based, common-sense regulations that foster innovation, conserve resources, and protect public healthespecially when it comes to the food supply, said Perdue.

The launch of this unified biotechnology regulation website is proof of President Trumps commitment to provide the American people with sensible regulations in a clear and transparent manner.

EPA is pleased to be working with our partners at USDA, FDA, and across the federal government to implement President Trumps Executive Order and launch this new, coordinated website, said EPA Administrator Wheeler.

This new website will help provide regulatory certainty and clarity to our nations farmers and producers by bringing together information on the full suite of actions the Trump Administration is taking to safely reduce unnecessary regulations and breakdown barriers for these biotechnology products in the marketplace, Wheeler said.

This is a time of unprecedented scientific innovation. Agricultural biotechnology promises to bring dynamic new products to the marketplace, said FDA Commissioner Stephen Hahn, M.D.

At the FDA, we are committed to fostering flexible, risk-based approaches in this field while upholding our mission of protecting and promoting both human and animal health and animal well-being, Hahn said.

For example, by reducing their susceptibility to diseases like novel influenzas and resistance to zoonotic or foreign animal diseases. Our approach balances our internationally respected, science-based review standards, Hahn said, with our ongoing risk-based regulatory approaches to ensure the safety of our food supply.

Background

The Unified Website for Biotechnology Regulation describes the federal review process for certain biotechnology products and allows users to submit questions to the three agencies.

The goals of this website are to provide enhanced customer service to innovators and developers, while ensuring Americans continue to enjoy the safest and most affordable food supply in the world and can learn more about the safe use of biotechnology innovations.

For more information, visit https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/home/.

Read more:
Unified website for biotechnology regulation recently launched - Daily Herald

Read More...

Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors – BioSpace

April 19th, 2020 1:45 am

IRVINE, Calif., April 17, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuros Board of Directors effective immediately. Dr. Klein, Chief Development Officer of PTC Therapeutics, Inc. (PTC), is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon. He succeeds Marcio Souza, who joined ClearPoint Neuros Board as PTCs representative in connection with PTCs May 2019 equity investment in ClearPoint Neuro. Mr. Souza, who resigned from his position as PTCs Chief Operating Officer, as was announced by PTC on March 16, 2020, will remain on ClearPoint Neuros Board as an independent member.

Prior to joining PTC, Dr. Klein served in several executive positions with BioElectron Technology Corporation (BioElectron), most recently as BioElectrons Chief Executive Officer and a Director prior to its acquisition by PTC in 2019. Dr. Klein has a BA from the University of Pennsylvania, an MD from Yale University School of Medicine and an MS in epidemiology from the University of Washington School of Public Health.

We are thrilled by the addition of Matt to our board and the contributions he will make to our company and culture, commented Joe Burnett, President and CEO. As a patient-centric company, adding an established physician, scientist and leader to our board will improve our ability to evaluate new technologies and partnerships.

I am very excited to be joining ClearPoint Neuros Board and look forward to bringing my experience as a drug developer and a surgeon to help the company continue its growth and to fulfill its incredibly important mission, said Dr. Klein.

About ClearPoint Neuro

ClearPoint Neuros mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Companys current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the United States. The Companys SmartFlow cannula is being used in partnership or evaluation with more than 20 individual biologics and drug delivery companies in various stages from preclinical research to late stage regulatory trials. To date, more than 3,500 cases have been performed and supported by the Companys field-based clinical specialist team which offers support and services for our partners. For more information, please visit http://www.clearpointneuro.com.

Forward-Looking Statements

Statements herein concerning the Companys plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the Companys ClearPoint Neuro Navigation System products; the Companys ability to market, commercialize and achieve broader market acceptance for the Companys ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Companys cash resources. More detailed information on these and additional factors that could affect the Companys actual results are described in the Risk Factors section of the Companys Annual Report on Form 10-K for the year ended December 31, 2019, which has been filed with the Securities and Exchange Commission.

Contact:Harold A. Hurwitz, Chief Financial Officer(949) 900-6833hhurwitz@clearpointneuro.com

Jacqueline KellerVice President, Marketing(949) 900-6833jkeller@clearpointneuro.com

Here is the original post:
Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors - BioSpace

Read More...

Is bluebird bio Inc (BLUE) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

April 19th, 2020 1:45 am

The 38 rating InvestorsObserver gives to bluebird bio Inc (BLUE) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 19 percent of stocks in the Biotechnology industry, BLUEs 38 overall rating means the stock scores better than 38 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

bluebird bio Inc (BLUE) stock is trading at $55.58 as of 1:27 PM on Friday, Apr 17, a gain of $3.02, or 5.75% from the previous closing price of $52.56. The stock has traded between $53.64 and $56.80 so far today. Volume today is high. So far 1,578,260 shares have traded compared to average volume of 1,164,930 shares.

To see the top 5 stocks in Biotechnology click here.

Go here to read the rest:
Is bluebird bio Inc (BLUE) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Viewpoint: How consumer fear and misguided regulation limit the progress of crop biotechnology – Genetic Literacy Project

April 19th, 2020 1:45 am

Theres a profound disconnect between what the latest gene-editing methods can do to increase yields and enhance crop disease and stress resistance and the trickle of such improved crops actually getting out into farmers fields.

The first generation of genetically modified (GM) crops has been remarkably successful. The whole world eats food containing ingredients derived from GM crops and feeds them to its myriad agricultural animals and pets. Despite many dire predictions of long-term negative health effects, a quarter century has passed and none have materialized.1 This remarkably clean track record should have assuaged public fears and assured the rapid development and adoption of GM crops of all kinds.

But it hasnt.

Decades after four major commodity biotech crops corn, soybeans, cotton and canola were introduced and rapidly soared to near market saturation in the countries that permitted their cultivation, the number of new GM crops being released to farmers remains tiny.

[Editors note: This article is part one of a four-part series on the progress of agricultural biotechnology. Read part two, part three and part four.]

Yet the need for higher yielding, disease-resistant and stress-tolerant crops grows with each passing year. The pressures of population growth and climate warming are already outpacing the speed with which conventional breeding practices are expanding the global food supply.2 Land and water availability are rapidly becoming limiting, hence the focus is sharply on the intensification of agriculture.3 But the breeding methods that fueled the spectacular advances in agricultural productivity over the 20th century are near exhaustion.

Over the same period, knowledge of plant physiology and genetics has grown at an explosive pace, as has the technology for identifying and modifying genes of agronomic interest. We know vastly more about what genes do and how plant genomes change both naturally and under human intervention than we did even when the first GM crops were introduced in 1996.4

The recent invention and rapid development of gene- or genome-editing technology (aka SSN or sequence-specific nuclease technology) has facilitated a quantum leap in the ease and precision of genetic intervention, positioning researchers to accelerate the increase in crop yields and to make crop plants more resilient to the biotic and abiotic stresses exacerbated by climate warming.5

Yet just a few of the crops that need to be improved are being improved using the latest techniques and of those, only a few reach farmers each year. To understand this deep disconnect between what can be done to improve crops using modern molecular techniques and what is being done requires a look at the tangle of issues around GM technology at the interface between science, business and society.

In this four-part series, I first examine the factors that led to the disconnect between what can be done and what is being done. I then review both the successes and failures of the first generation of GM crops modified using recombinant DNA (rDNA) technology. I next introduce the new gene-editing technologies and what they promise. And finally, I take a look at the regulatory, political and business decisions that actually determine what gets out of research laboratories and into farmers fields. The entire essay is available as a single publication from the author. Please email [emailprotected].

Part 1: The origins of the disconnect between the science and the farmer

Public resistance to innovation is not unusual, but hardly universal. People line up for the newest Apple iPhone, but have to be persuaded to try a GM apple that doesnt turn brown. Resistance generally subsides as a technology is widely adopted and proves harmless. GM technology in medicine, for example, is now broadly accepted, be it human insulin or any of the many new protein-based therapeutics. But the controversies around GM crops have persisted, and indeed intensified through the deliberate vilification efforts of both individuals and organizations.6,7

According to polls, the public remains largely ignorant of what GM organisms (GMOs) are and of how modern molecular methods fit into the long history of crop improvement.8 Because fear-based disinformation strategies are so effective, what has grown instead is the widespread conviction that GMOs are bad, meaning variously that they are harmful to health, unnatural, or produced by big biotech companies that unfairly exploit farmers.7,9

Part of the problem is that public awareness of genetic modification in agriculture is recent, arguably dating back only to the late 1980s when controversies erupted over field testing of the so-called ice-minus bacterium modified to eliminate a protein that promotes ice formation on the leaves of strawberries.10 Yet in a strictly scientific context, genetic modification denotes the entire spectrum of human interventions in the genetics of other organisms over more than 10 millenia.11

For crop plants, these encompass domestication, breeding, mutation breeding and, most recently, genetic improvement by molecular techniques. All involve genetic changes, aka mutations. Domestication and conventional plant breeding rely on organisms inherent genetic variation.

Direct genetic manipulation of crop plants using chemical and radiation mutagenesis (mutation breeding) dates back to the 1930s.12 But even now, few people other than plant breeders are aware that crops have long been improved through deliberate efforts to induce new mutations using both chemicals and irradiation. So today, it is the general understanding that genetically modified organisms (GMOs) are only those that have been modified by molecular methods. That is, most people think genetic modification is quite new.

And then theres what the regulators built

As if this were not sufficiently problematic, the way in which the regulatory environment evolved reinforced suspicions about GM safety. Early efforts to regulate the commercial introduction of GM crops emphasized the need to regulate new crop traits rather than the particular method by which they were introduced. But thats not what happened.

Starting from the beginning of the regulatory activities in the late 1980s, the U.S. agencies that oversee GM organisms have regulated only organisms modified by molecular methods and theyve regulated all of them, without regard to either nature of the organism or the trait that was added.13 This has been true of the US Department of Agriculture (USDA) and the Environmental Protection Agency (EPA), although the Food and Drug Administration has generally followed its practice of post-market oversight. None of the agencies subjected new crop varieties produced by the older methods of chemical and radiation mutagenesis to regulatory oversight.

Complying with the regulatory requirements proved not only time consuming and prohibitively expensive to developers,14 but also reinforced the altogether unfounded popular conviction that molecular methodology is dangerous. Both negative popular views of GM foods and the high regulatory costs associated with their introduction have shaped the present availability of GMOs in agriculture. Indeed, it is virtually impossible to understand the contemporary paucity of GM crop varieties without considering both regulatory and acceptance issues.

The recent development of gene-editing methods has led to a new round of public and bureaucratic controversy worldwide over what should be classified as a GMO and subject to regulatory oversight. Because gene-editing techniques15 introduce the same kinds of mutations as the older mutagenesis methods, crops modified by gene editing can be indistinguishable at the molecular level from those improved by mutation breeding.

Mutation breeding has been in safe use for a century, hence there is no scientifically defensible rationale for imposing regulations on crops with the same kinds of genetic changes produced by the new, far more precise methods. This is being recognized in some countries by decreasing the regulatory burden on certain types of crop modifications produced by gene-editing techniques.

However, in 2018 the European Court of Justice ruled that gene-edited crops should undergo the same level of regulatory scrutiny as crops modified by older molecular methods.16 As they have over the past 4 decades, the outcome of such regulatory decisions will profoundly influence the kinds of genetic improvements that will be undertaken and actually become available to farmers and consumers.

Thus both public opinion and regulatory practices have made major contributions to the disconnect between the modern science of crop improvement and the farmer.

1EC (2010). A decade of EUfunded GMO research (20012010). European Commission https://ec.europa.eu/research/biosociety/pdf/a_decade_of_eu-funded_gmo_research.pdf; NASEM (2016). Genetically Engineered Crops: Experiences and Prospects. National Academies of Sciences, Engineering, and Medicine 978-0-309-43735-6 http://www.nap.edu/catalog/23395/genetically-engineered-crops-experiences-and-prospects

2Ray DK et al. (2013). Yield trends are insufficient to double global crop production by 2050. PloS One 8:e66428.

3Tilman D et al. (2011). Global food demand and the sustainable intensification of agriculture. Proc Natl Acad Sci USA 108:20260-4.

4Richroch AE (2013). Assessment of GE food safety using -omics techniques and long-term animal feeding studies. New Biotechnol 30:351-54; Fedoroff NV (2013). Plant transposons and genome dynamics in evolution. (Wiley-Blackwell, Oxford, UK), p.212; Anderson JE et al. (2016). Genomic variation and DNA repair associated with soybean transgenesis: a comparison to cultivars and mutagenized plants. BMC Biotechnol 16:41.

5Podevin N et al. (2013). Site-directed nucleases: a paradigm shift in predictable, knowledge-based plant breeding. Trends Biotechnol 31:375-83; Zhang D et al. (2016). Targeted gene manipulation in plants using the CRISPR/Cas technology. J Genet Genomics 43:251-62; Zhang Y et al. (2019). The emerging and uncultivated potential of CRISPR technology in plant science. Nature Plants 5:778-94.

6Apel A (2010). The costly benefits of opposing agricultural biotechnology. New Biotechnol 27:635-40.

7Ryan CD et al. (2019). Monetizing disinformation in the attention economy: The case of genetically modified organisms (GMOs). European Management J 38:7-18.

8Funk C et al. (2015). Public and scientists views on science and society. Pew Research Center http://www.pewinternet.org/2015/01/29/public-and-scientists-views-on-science-and-society/

9Funk C and Kennedy B (2016). Public opinion about genetically modified foods and trust in scientists connected with these foods. Pew Research Center http://www.pewinternet.org/2016/12/01/public-opinion-about-genetically-modified-foods-and-trust-in-scientists-connected-with-these-foods/

10Palca J (1986). Ice-minus bacteria: Further snag and further delay. Nature 320:2.

11Fedoroff NV (2015). Food in a future of 10 billion. Agricult Food Security 4:11.

12Ahloowalia B et al. (2004). Global impact of mutation-derived varieties. Euphytica 135:187-204.

13Fedoroff NV (2013). Will common sense prevail? Trends Genet 29:188-9; Wolt JD et al. (2016). The regulatory status of genomeedited crops. Plant Biotechnol J 14:510-8; Van Eenennaam A and Fedoroff N. How the federal government can get biotech regulation right. Des Moines Register, 1 March 2018

14McDougall P (2011). The cost and time involved in the discovery, development and authorisation of a new plant biotechnology derived trait. Crop Life International https://croplife.org/plant-biotechnology/regulatory-2/cost-of-bringing-a-biotech-crop-to-market/

15Kleter GA et al. (2019). Gene-edited crops: towards a harmonized safety assessment. Trends Biotechnol 37:443-7.

16Kupferschmidt K (2018). EU verdict on CRISPR crops dismays scientists. Science 361:435.

Nina V. Fedoroff is an Emeritus Evan Pugh Professor atPenn State University

The rest is here:
Viewpoint: How consumer fear and misguided regulation limit the progress of crop biotechnology - Genetic Literacy Project

Read More...

Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? – InvestorsObserver

April 19th, 2020 1:45 am

The 72 rating InvestorsObserver gives to Iovance Biotherapeutics Inc (IOVA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, IOVAs 72 overall rating means the stock scores better than 72 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock has risen 13.99% while the S&P 500 is unchanged 0% as of 9:50 AM on Tuesday, Apr 14. IOVA is higher by $4.23 from the previous closing price of $30.23 on volume of 285,317 shares. Over the past year the S&P 500 is down -4.95% while IOVA is higher by 209.06%. IOVA lost -$1.59 per share the over the last 12 months.

To screen for more stocks like IOVA click here.

Excerpt from:
Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? - InvestorsObserver

Read More...

Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

April 19th, 2020 1:45 am

Inovio Pharmaceuticals Inc (INO) is near the top in its industry group according to InvestorsObserver. INO gets an overall rating of 72. That means it scores higher than 72 percent of stocks. Inovio Pharmaceuticals Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 6 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Inovio Pharmaceuticals Inc (INO) stock has risen 8.82% while the S&P 500 is lower by -0.22% as of 10:32 AM on Thursday, Apr 16. INO is up $0.63 from the previous closing price of $7.14 on volume of 5,210,923 shares. Over the past year the S&P 500 is down -4.25% while INO is up 108.87%. INO lost -$1.21 per share the over the last 12 months.

To screen for more stocks like INO click here.

See more here:
Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Investors should be cautious on the potential for Gilead’s drug Remdesivir, analysts say – CNBC

April 19th, 2020 1:45 am

A new report from STAT News on Gilead's experimental drug Remdesivir serves as an encouraging update on the drug's potential to fight Covid-19, however analysts argue it's largely anecdotal and should be interpreted with caution.

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS, both caused by coronaviruses.

According to the report from an ongoing phase three trial at a University of Chicago hospital, patients showing severe Covid-19 symptoms who were given the drug saw rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than one week.

Gilead commented that, "the totality of the data need to be analysed in order to draw any conclusions from the trial," in a statement to Reuters. A statement from the University of Chicago Medicine said that "drawing any conclusions at this point is premature and scientifically unsound."

Jefferies equity analyst Michael J. Yee published in a research note that this Chicago report provides an "incremental positive" but he assumes this significant short-term move in Gilead's share price will probably pull back a bit given eventual broader awareness that this is not the actual phase three data and that this is overdone in the near term.

JPMorgan biotechnology equity analysts wrote in a published research note Thursday that "this clinical trial experience appears to represent another encouraging, albeit largely anecdotal, data point for this high-profile drug candidate."

Meanwhile, the Barclays health-care team called the update "encouraging" but note that questions persist.

The report from the Chicago hospital comes amid mounting anecdotal evidence supporting the drug's potential effectiveness in treating the virus. Last week, the New England Journal of Medicine published an analysis showing that two thirds of a small group of severely ill patients saw their condition improve after taking the drug. These patients were given Remdesivir as part of a compassionate use program which allows doctors to provide patients with unauthorized treatments when no other treatment is available.

There was no control group in the University of Chicago study. As CNBC's Meg Tirrell has highlighted, this is not controlled clinical trial data it is a glimpse into what one of the sites that is running the trial is seeing.

The information reported by STAT News came from an internal discussion among faculty members at a University of Chicago hospital captured on video, it was not official data released by Gilead or any other trial leader.

Furthermore, this data comes from a single trial site. The Barclays health-care equity research team wrote: "While these data are encouraging, they are uncontrolled and from a single center."

Jefferies echoes this point: "Similar to the NEJM publication last week, yesterday's reports are based on one site and there is no placebo."

There is also debate around the severity of the patients included in the study. This data is part of an ongoing phase three trial of patients with severe Covid-19 symptoms. However, the patients were not intubated to start the study. Barclays adds that there will be debate around the patient population and how they compare to past cohorts.

"There's still a great deal we don't know, and thus we hesitate to put too much into the results generated at a single center without a control group," said JPMorgan.

"Fortunately, we don't have to wait long for a Phase 3 readout in severe patients."

Gilead expects results from its trials with patients with severe Covid-19 later this month. Data from its trials on patients with moderate symptoms is expected in May.

In addition to these two trials being run by Gilead, there are several others underway concurrently to evaluate Remdesivir, including a phase two trial run by the National Institute of Health which is an adaptive, randomized, double-blind, placebo-controlled trial.

Barclays adds that data from Gilead's clinical trials on severe cases due at the end of this month could support approval or expanded use authorization. A treatment is not going to end the pandemic. But it will provide a critical bridge to the ultimate panacea a vaccine.

CNBC's Berkeley Lovelace contributed to this article.

Read more:
Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts say - CNBC

Read More...

Researchers find rheumatoid arthritis drug is promising coronavirus treatment – New York Post

April 19th, 2020 1:44 am

Researchers at Georgia State University have found that auranofin, a drug approved for rheumatoid arthritis, may be an effective treatment against the coronavirus.

The team set out to study how drugs already approved by the Food & Drug Administration interact with the virus, known among scientists as SARS-CoV-2.

Drug repurposing is the fastest way to get a treatment for SARS-CoV-2, because its already been established that these medicines are safe to use in humans, says Mukesh Kumar, lead author of the study, in a press release on GSUs website. Kumar and his colleagues shared their work on bioRxiv for peer review.

Like all viruses, COVID-19 cannot self-reproduce. It needs host cells animal or human in order to make copies of itself.

Effective drugs need to interfere with this replication process, shutting down the virus ability to proliferate inside the host, says Hussin Rothan, a co-author of the study.

With auranofin, the coronavirus was cut down by 95% in human cells within 48 hours, and inflammation caused by the disease was significantly mitigated.

One of the primary causes of death in COVID-19 patients is a syndrome called a cytokine storm, wherein the bodys healing response to illness goes haywire, causing immune cells to attack healthy tissue, leading to organ failure. Cells treated with auranofin, however, saw a significant drop in cytokines, the proteins that signal immune cells to attack.

This shows that the drug not only could inhibit replication of SARS-CoV-2, mitigating the infection, but also reduce the associated lung damage that often leads to severe respiratory distress and even death, says Kumar.

Auranofin, including the brand-name drug Ridaura, was approved by the FDA in 1985. The drug is unique for being partially composed of gold particles, which have been used for centuries for their anti-inflammatory properties. Treatments involving gold compounds have also been considered for use against HIV, cancer, neurodegenerative disorders, and parasitic and bacterial infections.

The team at Georgia State University says they plan to continue their study on how auranofin impacts the coronavirus in animal models.

Read more:
Researchers find rheumatoid arthritis drug is promising coronavirus treatment - New York Post

Read More...

What To Know About COVID-19 And Arthritis – South Florida Reporter

April 19th, 2020 1:44 am

According to theArthritis Foundation, people with autoimmune or inflammatory arthritis with high disease activity generally have a higher risk of infections due to reduced immune function.

Regarding children with arthritis, the Arthritis Foundation suggests that factors such as arthritis type, disease activity, the involvement of organs, and the level to which their immune system is suppressed may all play a role in the risk of coronavirus infection.

Someresearchsuggests that people with rheumatoid arthritis (RA) have an increased risk of infection because their immune system is impaired. This is typical in autoimmune conditions such as RA.

Furthermore, these people may take medications such as corticosteroids and immunosuppressive drugs that also affect immune function. This may increase their risk of contracting the virus.

The presence of other underlying conditions, such as diabetes or heart disease, can further increase risk.

There is not yet enough evidence to confirm this, but it seems that people with autoimmune or inflammatory arthritis may be at higher risk of infection or severe COVID-19 symptoms.

TheCenters for Disease Control and Prevention (CDC)report that conditions or medications that weaken the immune system increase the risk of severe illness with COVID-19.

Expertssuggest that the main concerns for those with autoimmune conditions who develop COVID-19 include secondary bacterial infections and other complications that may result from the initial viral infection.

In general, those who take immunosuppressive medications, such as biologics or corticosteroids, are at higher risk of a severe viral infection. People who take immunosuppressive medications and who develop flu-like symptoms should call their doctor immediately.

Healthcare professionals typically do not recommend immunosuppressive treatments in those with active infections, but the risk of disease flares is also worth consideration. A person can determine whether to discontinue, taper, or maintain their medication by consulting their doctor.

Those who take immunosuppressive drugs and who do not have symptoms of COVID-19 should discuss their options with their doctor. In some cases, the risk of arthritis flares may outweigh the potential benefits of stopping treatment.

In either case, it is important that people do not adjust their dosage or stop taking their medication without first seeking medical advice.

Visit link:
What To Know About COVID-19 And Arthritis - South Florida Reporter

Read More...

Veterinary Orthopedic Implants Market Forecast, 2020-2030 – Increase in Incidence of Obesity and Arthritis is Spurring Demand – ResearchAndMarkets.com…

April 19th, 2020 1:44 am

DUBLIN--(BUSINESS WIRE)--The "Veterinary Orthopedic Implants Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering.

The global veterinary orthopedic implants market was worth $98.11 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 7.64% and reach $131.71 million by 2023. North America is expected to be the largest for the period 2019-2025.

The increase in the incidence of obesity and arthritis increases the demand for veterinary orthopedic implants market. As reported by Banfield Pet hospital in U.S, in 2017, 31 per 100 cases suffered from obesity and 450 per 10,000 suffered from arthritis in dogs. Further, 34 per 100 cases suffered from obesity and 90 per 10,000 suffered from arthritis in cats. Thus, the increase in health conditions affecting the bones of pets such as obesity and arthritis positively affect the growth of the veterinary orthopedic market.

The high cost of orthopaedic surgery inhibits the growth of veterinary orthopaedic implants market. The surgery cost includes the equipment, X-ray, and consumables among others, which many of the households cannot afford. For instance, in the USA, a typical examination of the problem costs around $400 and the cost of orthopaedic surgery ranges from $1,500 to $4,000. Thus, the high cost of orthopaedic surgery restricts the growth of the veterinary orthopaedic market.

The companies in veterinary orthopaedic implants market are investing in 3D printing technique for creating veterinary orthopaedic implants. 3D printing in veterinary orthopaedics market is being used for creating printed bone models, surgical guides and titanium implants. The use of 3D printing reduces the surgical time, cost and removes the engineering complexities in orthopaedic procedures. Following the trend, many dogs with bone deformities have been treated by Langford Veterinary Services, a UK based provider of veterinary services, through its collaboration with CBM.

The collaboration enabled CBM to create 3D printed models of animal implants using titanium Ti6AI4V EL material. The MRI or CT scans are sent from Langford Veterinary Services in Bristol to CBM who then produces 3D printed models using Arcam EBM Q10plus machine. CBM is a U.K based company focused on advanced research, product development, and batch manufacturing facility. Thus, the use of 3D printing is one of the latest trends in veterinary orthopaedic implants market and will contribute to the growth of the market.

In 2019, Infiniti Medical, a USA based designer and distributor of medical devices for the veterinary market, acquired Orthomed Ltd. for an amount undisclosed. Through the acquisition, Infiniti Medical aims to expand its product portfolio by adding products and services from Orthomed. Orthomed Ltd is a UK based provider of orthopedic products and systems in veterinary industry.

Major players in the market are KYON Pharma, Inc., Veterinary Orthopedic Implants Inc., BioMedtrix, LLC, IMEX Veterinary Inc., Orthomed (UK) Ltd, Securos Surgical, B.Braun Vet Care, Bluesao and DePuy Synthes Vet.

Key Topics Covered

1. Executive Summary

2. Veterinary Orthopedic Implant Market Characteristics

3. Veterinary Orthopedic Implant Market Size And Growth

3.1. Global Veterinary Orthopedic Implant Historic Market, 2015-2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Veterinary Orthopedic Implant Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Veterinary Orthopedic Implant Market Segmentation

4.1. Global Veterinary Orthopedic Implant Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Veterinary Orthopedic Implant Market, Segmentation By Animal, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.3. Global Veterinary Orthopedic Implant Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Veterinary Orthopedic Implant Market Regional and Country Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/35hfp1

View post:
Veterinary Orthopedic Implants Market Forecast, 2020-2030 - Increase in Incidence of Obesity and Arthritis is Spurring Demand - ResearchAndMarkets.com...

Read More...

COVID-19: Potential impact on Systemic Idiopathic Juvenile Arthritis Treatment Market to Witness Widespread Expansion During 2019-2060 – Jewish Life…

April 19th, 2020 1:44 am

The report on the Systemic Idiopathic Juvenile Arthritis Treatment market provides a birds eye view of the current proceeding within the Systemic Idiopathic Juvenile Arthritis Treatment market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Systemic Idiopathic Juvenile Arthritis Treatment market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Systemic Idiopathic Juvenile Arthritis Treatment market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

The Systemic Idiopathic Juvenile Arthritis Treatment market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Systemic Idiopathic Juvenile Arthritis Treatment market and the trends that will prevail in this industry.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2534385&source=atm

What pointers are covered in the Systemic Idiopathic Juvenile Arthritis Treatment market research study?

The Systemic Idiopathic Juvenile Arthritis Treatment market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Systemic Idiopathic Juvenile Arthritis Treatment market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Systemic Idiopathic Juvenile Arthritis Treatment market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

The following manufacturers are covered:Alteogen Inc.Bristol-Myers Squibb CompanyEpirus Biopharmaceuticals, Inc.Johnson & JohnsonMomenta Pharmaceuticals, Inc.Mycenax Biotech Inc.Novartis AGOncobiologics, Inc.

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAdalimumab BiosimilarCanakinumabGolimumabTocilizumab BiosimilarOthers

Segment by ApplicationClinicHospitalOthers

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2534385&source=atm

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Systemic Idiopathic Juvenile Arthritis Treatment market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Systemic Idiopathic Juvenile Arthritis Treatment market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Systemic Idiopathic Juvenile Arthritis Treatment market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2534385&licType=S&source=atm

Some of the Major Highlights of TOC covers:

Read the original post:
COVID-19: Potential impact on Systemic Idiopathic Juvenile Arthritis Treatment Market to Witness Widespread Expansion During 2019-2060 - Jewish Life...

Read More...

Lower Treatment Effectiveness in Patients With RA and PsA With Insurance Restrictions for DMARDs – Medical Bag

April 19th, 2020 1:44 am

Compared with patients without access restrictions to biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) or with psoriatic arthritis (PsA) only, patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) whose insurance plans restrict access to these DMARDs have lower odds of treatment effectiveness, according to study results published in PharmacoEconomics Open.

According to the researchers, novel DMARDs can slow disease progression in RA and PsA; however, many health insurance plans require prior authorization or step therapy for access to these treatments. The objective of this study was to compare treatment effectiveness in patients with RA or PsA with and without plan-level access restrictions to biologic or targeted synthetic DMARDs, and also to compare medication adherence between each group.

Researchers used the IBM MarketScan Commercial Claims and Encounters Database to analyze data from patients aged 18 to 64 years with RA or PsA with 1 claims for subcutaneous biologic DMARDs between January 2014 and December 2015. Patients included in the study were stratified into 1 of 2 cohorts: RA with or without PsA, and PsA only. The primary outcome was treatment effectiveness during the 12 months after the first DMARD claim; the secondary outcome was adherence to the index medication. Multivariate analysis was used to examine differences in the primary outcome of treatment effectiveness between patients with and without DMARD access restrictions.

Researchers revealed that among patients with RA (n=3993) and PsA (n=1713), 34.2% and 35.1%, respectively, had plan-level access restrictions. Among patients with access restrictions, 70.5% and 78.9% of patients with RA and PsA, respectively, had plans that required step therapy. The odds of treatment effectiveness during the 12-month follow-up were 19% lower among patients with RA (odds ratio [OR], 0.81; 95% CI, 0.67-0.98; P =.033) and 27% lower among patients with PsA whose plans included step therapy (OR, 0.73; 95% CI, 0.5-0.98; P =.037) compared with patients whose plans did not include step therapy. The odds of medication adherence among patients enrolled in plans with vs without step therapy were 19% lower among patients with RA (OR, 0.81; 95% CI, 0.68-0.96; P =.014) and 29% lower among patients with PsA (OR, 0.71; 95% CI, 0.54-0.94; P =.017).

Study limitations included possible miscoding or undercoding of the datasets used, lack of control for several baseline characteristics and medication use behaviors in patients, and the inability to generalize data for patients who were uninsured or had other types of insurance plans.

Researchers concluded, Compared with patients in plans without access restrictions or with PsA only, patients [with] RA and PsA in insurance plans with step therapy had lower odds of treatment effectiveness, mainly [because of] lower odds of adhering to treatment, during the 12 months [after] subcutaneous [biologic] DMARD initiation.

Disclosure: This clinical trial was supported by Elli Lilly and Company. Please see the original reference for a full list of authors disclosures.

Reference

Boytsov N, Zhang X, Evans KA, Johnson BH. Impact of plan-level access restrictions on effectiveness of biologics among patients with rheumatoid or psoriatic arthritis. Pharmacoecon Open. 2020;4(1):105-117.

This article originally appeared on Rheumatology Advisor

See more here:
Lower Treatment Effectiveness in Patients With RA and PsA With Insurance Restrictions for DMARDs - Medical Bag

Read More...

Efficacy of laser therapy in veterinary medicine: thoughts from a novice – dvm360

April 19th, 2020 1:42 am

Christian Mller / stock.adobe.com

Like many clinicians, I find it daunting to stay current with the many evolving topics in veterinary medicine. Photobiomodulation (also referred to as low-level laser therapy [LLLT] or cold laser) represents a particularly challenging modality to approach for several reasons. For one, colleagues who know more about LLLT than I do have a wide range of often strong opinions regarding its effectiveness. Also, the biophysics involved are less familiar to me than are other aspects of veterinary medicine. Nevertheless, the use of LLLT is quickly becoming widespread for a wide range of applications, and I thought I should learn a bit more about it.

For those who can relate, what follows is my novice attempt to reach an evidence-based and open-minded opinion about the efficacy of LLLT in small animal patients.

As I started my inquiry, I found that an American Society of Laser Medicine and Surgery exists, with an official journal: Lasers in Surgery and Medicine. This journal ranks in the top 25% for journal impact factor (which reflects frequency of citation) for both dermatology and surgery.

After reading articles in this journal and related others, two things stood out to me:

From what I did read, the benefits of LLLT in people and laboratory models are numerous: cosmetic skin applications, wound healing, edema reduction, return to function from sports injuries, improving vaginal health, dental healing, head trauma recovery and many more. The efficacy of LLLT did seem hard to discount after this reading. Of the studies that reported discouraging results, most generally concluded with confidence that optimization of protocols would improve outcomes.

Because I lacked a clear, evidence-based conclusion from my broad review, I turned specifically to the veterinary literature. Searching for small animal investigations from major journals, I found nine recent publications. All happened to study dogs, and applications of LLLT were identified in dermatology, tibial plateau leveling osteotomy (TPLO) and intervertebral disk disease (IVDD).

Most of the veterinary research on LLLT relates to applications for the skin. Two recent articles evaluated the use of laser for wound healing in healthy skin. In the first study, the investigators created and then closed 20 incisions in intact male beagles.1 No differences were found between LLLT or sham treatment for epithelization, contraction or histopathology. The same study also looked at the effect of LLLT on 20 incisions that were left open to heal, and again found no effect.

In a second study,2 LLLT was used in 10 female dogs during bilateral flank spay procedures. The investigators found relatively less necrosis and fewer perivascular lymphocytes in the incisions in the LLLT group at day 7, but more perivascular lymphocytes in the LLLT group at day 14. No differences were found between groups visually during healing or with any other histologic variable. Taken together, these two studies of healing of healthy skin with LLLT are discouraging.

Two studies investigated LLLT use in abnormal skin. In a 2014 study published in Veterinary Dermatology, Olivieri et al.3 reported a dramatic improvement in canine noninflammatory alopecia using LLLT, in that much more fur grew with LLLT than in a control group. In the same journal and year, Stich and colleagues4 found no effect of LLLT on pedal pruritis due to atopy.

Three reports on the use of LLLT in promoting healing after TPLO surgery have been published since 2017. The largest study, reported in Veterinary Surgery in 2018,5 examined 95 dogs and found LLLT-associated improvement with regard to owner assessment of gait. No improvement was seen with regard to pain management or radiographic healing. Results of a 2017 study6 showed that LLLT was associated with improved surgical limb function eight weeks postoperatively in 27 dogs undergoing TPLO, as evidenced by more force applied to a plate. The smallest study,7 involving 12 dogs, found more lameness and more pain during the first postoperative month in the LLLT group. The investigators found no differences at 8 weeks, or at any time point, radiographically or cytologically. So, the two larger studies were encouraging, and the smallest one was discouraging.

Two reports on dogs undergoing hemilaminectomy examined postoperative use of LLLT. A 2012 study involving 36 dogs demonstrated dramatic shortening of time to return to ambulation with LLLT (median of 3.5 days vs. 14 days for controls).8 A study from 2017 compared 11 dogs treated with LLLT postoperatively with 10 dogs treated with sham LLLT.9 No differences were found between the LLLT and sham groups at several recovery benchmarks, including initial limb movement, ability to stand with some support, ability to walk at least three steps, and ability to walk at 10 days.

Making a broad conclusion about the effectiveness of LLLT based on the above nine canine studies is fraught on several levels, including that the studies involve different disease states and different protocols. Considering that substantial caveat, however, I can draw one conclusion: Five of these nine studies (55%) revealed at least one metric showing a benefit of LLLT compared with control.

Of note, the above text was reviewed at a well-regarded specialty facility that commonly uses LLLT. Feedback included the facts that several of the referenced discouraging studies were flawed by not reporting all critical parameters, and that such discouraging results could be attributed to underdosing, which is often a problem in the use of LLLT.

While this article was undergoing review, Veterinary Dermatology published an article on the use of LLLT in 36 dogs with interdigital pyoderma.10 The investigators found that LLLT shortened resolution of lesion time from 10.4 to 4.3 weeks.

Now at the end of my initial attempt to form an opinion on LLLT efficacy in small animal patients, I would emphasize my humility in the face of others expertise. That noted, following are my conclusions from exploring the recent articles about LLLT in major small animal publications:

I look forward to further research as it becomes available, of course, but I now feel comfortable referring cases for LLLT as long as the status of current research is made clear to clients.

Dr. Levinson became board certified in veterinary emergency and critical care in 2010. He practices at Brenford Animal Hospitals in Dover, DE, where his interests include echocardiography and fostering a Fear Free environment.

References

Follow this link:
Efficacy of laser therapy in veterinary medicine: thoughts from a novice - dvm360

Read More...

Faculty for TTUs School of Veterinary Medicine continues to grow – KLBK | KAMC | EverythingLubbock.com

April 19th, 2020 1:42 am

LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

The faculty for the Texas Tech UniversitySchool of Veterinary Medicine in Amarillocontinues to take shape with the addition of Nancy Zimmerman as a professor of small animal surgery.

A native of Pennsylvania, Zimmerman comes to Texas Tech from Arena, Wisconsin. For the last 15 years she has helped teach veterinary students from the University of Wisconsin and other teaching hospitals in the U.S. and Canada. In addition, she has provided continuing education to domestic and international veterinarians.

When I learned about the opportunity to build a teaching program at Texas Tech that would focus on training students, that was very interesting to me, Zimmerman said. We have an opportunity to utilize the most current methods and technology to help students learn and grow through the training process of becoming a veterinarian. Im really keen on being a part of that and trying to impart some of the clinical experience Ive gained working in many different capacities as a veterinarian over the past 20 years

Zimmerman earned her Doctor of Veterinary Medicine from the University of Wisconsin Madison in 1998. She completed a Small Animal Surgery residency at Virginia Tech and earned her Master of Science degree in 2003. Zimmerman earned board certification and was named a Diplomate of the American College of Veterinary Surgeons (ACVS) in 2004.

After completing her surgery residency, Zimmerman worked as an associate in a private referral hospital in Dallas. In 2006, she relocated to Wisconsin and established a small animal locum surgery practice, Gentle Hands Veterinary Specialists. Zimmerman worked as a small animal surgeon at private referral practices and university teaching hospitals in the U.S. and Canada, providing care for patients and helping students, residents and interns learn clinical applications of veterinary surgery.

When Zimmerman was not working away from home, she helped manage the lamb and beef farm that she owned in Wisconsin. She hosted workshops and seminars on the farm several times each year to help veterinary students and regional livestock producers learn about small ruminant husbandry.

As a professor of small animal surgery for Texas Tech School of Veterinary Medicine, Zimmerman will share her rich experience and surgical skills and knowledge with a broader audience.

It is important to focus on the patient and the client, Zimmerman said. My goal is to work with Texas Tech University practice partners, who will serve as clinical training centers for veterinary students, to develop programs that graduate veterinarians who will not only be competent and have the knowledge but also confident to do what they need to do to provide the best, most complete service to their patients and clients, with compassion.

Guy Loneragan, dean of the School of Veterinary Medicine, said it is Zimmermans caring nature that makes her a great fit.

She cares about practicing high-quality, compassionate veterinary medicine, Loneragan said. She also has experience mentoring students in real-world settings, and she cares about helping them become the best they can be. Our students are going to benefit so much from her instruction and, in turn, the clients of our future graduates will benefit. We are so fortunate Dr. Zimmerman chose to join the Texas Tech family.

A strength Zimmerman feels she will bring veterinary students is the ability to be versatile, noting there is more than one way to accomplish a goal. The aim in veterinary practice is to determine the end goal of treatment and how best to achieve that goal. An important aspect of being a veterinarian is to be able to adapt, she says. Veterinarians need to be able to see the big picture and think through problems to find solutions based on an understanding and application of concepts and principles rather than memorized protocols.

Dr Zimmerman has a great reputation for providing continuing education and teaching surgical skills, said John Dascanio, senior associate dean of the School of Veterinary Medicine. She is passionate about bringing those talents to Texas Tech to raise the bar to help veterinary graduates be practice-ready on day one. Dr. Zimmerman will help our students walk out our doors as confident, competent young surgeons.

Zimmerman joins Loneragan, Dascanio, associate dean for clinical programs Britt Conklin, large animal surgery professor David Dutton, assistant professor Bethany Schilling and large-animal medicine professor Lszl Hunyadi on the faculty for the School of Veterinary Medicine. Additional faculty members will be added over the summer and fall.

Having a broad scope of diverse experiences in veterinary medicine makes you a great practitioner, but more importantly, it makes you a better teacher, Conklin said. Dr. Zimmerman has had an enormous breadth of experiences that will allow her to deliver an unmatched educational experience to our student body and, additionally, will provide our practice partners with a wealthy resource.

About the School of Veterinary Medicine

Thanks to the generosity of Amarillo and communities across Texas, and the commitment of legislators from around the state, the Texas Tech University School of Veterinary Medicine in Amarillo, established in 2018, is working to enroll its first class in the fall of 2021, pending approval by the AVMA Council on Education.

The School of Veterinary Medicine will recruit and select students with a passion to practice and succeed in small, agricultural and regional communities and utilize a curriculum focused on the competencies and skills necessary to be successful in practices that support these communities. Texas Techs innovative and cost-efficient model partners with the wider community of veterinary practices across the state to provide clinical, real-world experiential learning.

In June, Gov. Greg Abbott signed into law the biennial state budget, which appropriated $17.35 million for the School of Veterinary Medicine in Amarillo that will go toward operational needs in order to get the school up and running. The appropriation included language directing Texas Tech to move forward in establishing the school.

Donors and civic leaders have pledged more than $90 million toward infrastructure, construction and scholarships for the School of Veterinary Medicine on the site of Texas Tech University Health Sciences Center in Amarillo.

(News release from Texas Tech University)

Read this article:
Faculty for TTUs School of Veterinary Medicine continues to grow - KLBK | KAMC | EverythingLubbock.com

Read More...

What is the role of animals in veterinary education? – American Veterinary Medical Association

April 19th, 2020 1:42 am

Animals in veterinary education were one of the key topics during several sessions at the Association of American Veterinary Medical Colleges 2020 Annual Conference and Iverson Bell Symposium, March 8-10 in Washington, D.C. The Use of Animals in Education symposium focused on how animals are used in veterinary colleges curricula.

We had a good open discussion, said Dr. Dean Hendrickson, Colorado State University, in an interview afterward with JAVMA News. The big thing is the excitement. Where do we want to go, and what do we want to do?

The event included several key goals for educators. Among them was starting a conversation on how each veterinary college is currently using animals in its curriculum and what the use of animals may look like in the future.

Read the AAVMC policy on Use of Animals in Education andthe AVMA policy on Use of Animals in Research, Testing, and Education.

Dr. Phillip Nelson, the dean of the Western University of Health Sciences College of Veterinary Medicine, said it is necessary for leadership in veterinary academia to think about how the profession uses animals.

The founding faculty at the Western University veterinary college did just that. The Willed Deceased Animals for Veterinary Education program at the veterinary college encourages pet owners from 90 sites in Southern California to donate their pets remains to the veterinary college for anatomy and clinical skills education. The veterinary college uses models of animals and student-owned animals for routine procedures.

The Cummings School of Veterinary Medicine at Tufts University also has a willed-body program.

However, despite the success of the programs at these two universities, most veterinary colleges in the U.S. face challenges implementing similar programs because of the location of their campuses.

Unfortunately, there are a number of metro areas that would support a program, but veterinary schools are located in rural areas, and that creates separate challenges, Dr. Nelson said.

Western University is located in Pomona, California, about 30 minutes outside of Los Angeles, and Tufts University in Grafton, Massachusetts, is about 45 minutes west of Boston.

Although many veterinary colleges have had issues implementing willed-body programs, most have found it easy to include models of animals in the curriculum.

Dr. Julie Hunt, director of small animal clinical skills at the Lincoln Memorial University College of Veterinary Medicine, designed and developed the clinical skills curriculum at LMU.

Theres no question in my mind, Dr. Hunt said. You can absolutely teach and improve surgical skills using models. Early on, a huge amount of techniques can be used on models, and models can be used for practicing clinical skills repeatedly.

The models do not replace live surgery. But Dr. Hunt said she believes that animal models can be used instead of nonsurvival surgeries, which can cause stress and well-being issues for students.

The LMU curriculum includes a combination of live animals, cadavers, and models to teach students and for students to practice clinical skills.

Models may be a key tool for students, but cadavers are still important for early anatomy classes.

Dr. Jeremy Delcambre, assistant professor in the Department of Biomedical Sciences at Colorado State University College of Veterinary Medicine and Biomedical Sciences, said he wanted symposium attendees to question themselves.

Do you know where you cadavers are coming from? Have you done an audit on use and sustainability? Dr. Delcambre said.

There is a shortage of dog and cat cadavers and currently only one commercial supplier. So it may be time to adapt, he added.

Educators and veterinary leadership involved in the symposium plan to hold another event to continue the conversation but have not yet set a date.

Read the original here:
What is the role of animals in veterinary education? - American Veterinary Medical Association

Read More...

Veterinary medicine at the forefront in the fight against COVID-19 – dvm360

April 19th, 2020 1:42 am

Darryl / stock.adobe.com

Coronaviruses, so named for their knobby surface projections that create a crown-like appearance,1-3 were first identified in the 1930s but are thought to have originated more than 10,000 years ago.4,5 They and their associated illnesses have been observed in cattle, horses, cats, dogs, swine, rabbits, rodents and bats, among others.6,7

In humans, seven coronavirus strains have been identified, as have their bat and rodent reservoirs, and their intermediate hosts, including cattle, camels and civets.8-16 Most of these strains cause nothing more than the common cold in people, but threesevere acute respiratory syndrome (SARS),17 Middle East respiratory syndrome (MERS)18 and SARS-CoV-2have proven more daunting.

As the professionals with the most thorough understanding of One Health, veterinarians around the world have been working hard on COVID-19 diagnostic, prevention and treatment measures. Heres a look at some of the work being done.

At Cornell University College of Veterinary Medicine, a group of researchers have shunted their work to focus on SARS-CoV-2. Virology professor and coronavirus expert Gary Whittaker, PhD, who has done extensive research on MERS, is investigating the SARS-CoV- 2 spike protein and its mechanisms for fusing with the host cell.19 He hopes to apply his findings to drug and vaccine development. The team also includes investigators who are working on diagnostic tests for SARS-CoV-2.

Researchers at Louisiana State University School of Veterinary Medicine are working to develop a COVID-19 vaccine, slated to begin animal trials soon. The group, which includes investigators who study bovine coronaviruses, is collaborating with researchers at Tulane University, one of the first facilities to obtain samples of SARS-CoV-2 from the Centers for Disease Control and Prevention.

The coronavirus that afflicts cats and causes deadly feline infectious peritonitis (FIP) has long been a subject of research at the University of California, Davis, School of Veterinary Medicine. Investigators at the school have used an antiviral drug shown to block virus replication in monkeys and mice as a springboard for developing a protocol to treat FIP in cats experimentally infected with feline enteric coronavirus.20

"Its the virus-infected cells that are producing all of these nasty cytokines that are causing this inflammation, explains Niels Pedersen, DVM, PhD, who has been studying feline coronavirus for the past five decades, so if you can stop the replication cold in its tracks, you're going to immediately stop the cytokines from being produced."

Treatment has been largely successful in feline studies, which gives Pedersen hope for the nearly identical remdesivir, now in clinical trials for the treatment of SARS-CoV-2. If it can be done in cats, why can't it be done in humans?" he says.

The concept of drug repurposing might also be applied to the parasiticide ivermectin, an FDA-approved anti-parasitic agent for animals and humans that, in recent years, has been shown to have antiviral activity in vitro by interfering with virus replication.21-25 In vitro studies have demonstrated that ivermectin interferes with replication of many viruses, including human immunodeficiency virus 1,22 West Nile virus,23 dengue virus,22,24 Venezuelan encephalitis virus,25 simian virus,22,26 pseudorabies27 and influenza.21

A recent study,28 published in the journal Antiviral Research, demonstrates that ivermectin impedes SARS-CoV-2 in vitro.* Previous reports on similar coronaviruses describe the role of specific proteins in viral transport into the host nucleus, suggesting that ivermectins nuclear transport inhibitory activity may be effective against SARS-CoV-2.

Cells infected with SARS-CoV-2 were treated two hours post infection with a single dose of ivermectin at serial dilutions. At 24 hours, the addition of 5 M ivermectin produced a 99.8% reduction in cell-associated viral RNA, which increased to 99.98% at 48 hours; this equated to an approximately 5,000-fold reduction of viral RNA compared with control samples. No cell toxicity was observed at this concentration.

The studys Australian investigators, from Monash University and the Peter Doherty Institute for Infection and Immunity, hypothesize that ivermectin inhibits the IMP/1-mediated nuclear import of viral proteins, but they hope to confirm this mechanism in the case of SARS-CoV-2. The identification of the specific SARS-CoV-2 and/or host component(s) impacted is an important focus their future work.

This research sets the stage for development of an effective antiviral drug that, if given to patients early in infection, could reduce SARS-CoV-2 viral load, block disease progression and limit person-to-person transmission.

The answers to the COVID-19 pandemic will be shaped like medications and vaccines. And surely, they will be colored by extensive data established by the veterinary community.

*Editors note: The FDA has issued a public warning stating that people should not self-medicate with ivermectin in an effort to treat or prevent COVID-19. The warning reads, in part: FDA is concerned about the health of consumers who may self-medicate by taking ivermectin products intended for animals, thinking they can be a substitute for ivermectin intended for humans. People should never take animal drugs, as the FDA has only evaluated their safety and effectiveness in the particular animal species for which they are labeled. These animal drugs can cause serious harm in people. People should not take any form of ivermectin unless it has been prescribed to them by a licensed health care provider and is obtained through a legitimate source. For the full FDA letter, click here.

References

See the rest here:
Veterinary medicine at the forefront in the fight against COVID-19 - dvm360

Read More...

Caring for pets during the COVID-19 pandemic – The Ohio State University News

April 19th, 2020 1:42 am

The anxiety of trying to stay safe through the COVID-19 pandemic is not reserved only for the humans enduring stay-at-home orders and social isolation.

Pets might be anxious, too at the same time most are probably glad their owners are home all day, every day. Even good change can be hard for domestic animals to adjust to, says M. Leanne Lilly, assistant professor-clinical of veterinary clinical sciences at The Ohio State University.

Lilly, who specializes in veterinary behavioral medicine, was among a panel of College of Veterinary Medicine experts who addressed questions submitted by pet owners during an April 9 webinar.

Treat your pets like family. Remember this is a hard change for them, too, so make sure their behavioral needs are met, she said. There are more chances for inappropriate interactions from a pet perspective. Dont overdo it.

Be gentle with yourselves as youre being gentle with your pets.

Many questions from viewers revolved around a recent study in China that revealed cats and ferrets appear to be susceptible to getting sick after being inoculated with the novel coronavirus. The findings also suggested that cats could infect each other. The study found that dogs, pigs, chickens and ducks are able to resist the viruss efforts to make copies of itself and cause infection.

Jeanette OQuin, assistant professor-clinical of veterinary preventive medicine, said that the results of that single study need to be considered along with the rarity of natural cases in animals. Pet owners probably neednt worry much about risk of coronavirus infection to cats and dogs in their homes, she said.

Researchers introduced a very high dose of the virus to animals in the study. And the cats that were infected recovered without incident after having mild symptoms: respiratory problems, fever and lethargy, which are symptoms linked to many common pet illnesses.

What that study tells us is whats possible, but it doesnt really tell us whats probable, said OQuin, a specialist in infectious disease control. This is a distinctly human virus that passes readily from person to person.

The risk to animals is very low, and the risk from animals to people is even lower.

Essentially, the experts said that what it takes for humans to stay safe right now is also good for pets: Shelter in place together, avoid pet play dates and when walking dogs, keep them on a leash and maintain a safe distance between yourself and your pet and other owners and their dogs.

Owners who have tested positive for COVID-19 and dont have assistance with pet care should avoid cuddles and kisses and are advised to wear a cloth mask and wash their hands before and after contact with their pets.

Private practices and hospitals are taking special precautions to protect animal and human health if a pet requires veterinary care during the pandemic, said Roger Fingland, executive associate dean and chief medical officer of the college.

The first thing pet owners should do, even in an emergency, is make a phone call to their veterinarian, Fingland said. Some veterinarians with existing relationships with their clients may be able to give advice via telemedicine.

If a pet requires in-person care or hospitalization, pet owners should expect curbside drop-offs and pickups of their animals and frequent phone, email or text contact about a care plan. Visitation generally isnt allowed except in end-of-life cases.

Veterinarians are seeing mostly urgent and emergent cases, Fingland said. Very few elective procedures are being done. Thats to save PPE (personal protective equipment) for human use.

Ideally, pet owners should be able to pull together a quarantine kit of food and medication if two weeks of isolation are required. Recommended supplies, as well as information updates as conditions change during the pandemic, are available on the colleges website.

College of Veterinary Medicine Dean Rustin Moore noted that about three-fourths of American households have pets and that during difficult times, the love and companionship of a pet can make a real difference in human health.

Interacting with a pet has been shown through scientific evidence to have positive benefits on the physical and mental well-being of people, Moore said. Petting, snuggling, cuddling and looking into the eyes of a pet has been shown to lead to physiological changes in the human body.

Ninety percent of us who have pets consider them as part of our family. They should be treated as such during COVID-19.

Go here to read the rest:
Caring for pets during the COVID-19 pandemic - The Ohio State University News

Read More...

Page 588«..1020..587588589590..600610..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick